[go: up one dir, main page]

EA201590805A1 - COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY - Google Patents

COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY

Info

Publication number
EA201590805A1
EA201590805A1 EA201590805A EA201590805A EA201590805A1 EA 201590805 A1 EA201590805 A1 EA 201590805A1 EA 201590805 A EA201590805 A EA 201590805A EA 201590805 A EA201590805 A EA 201590805A EA 201590805 A1 EA201590805 A1 EA 201590805A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immediate
composition
prolonged delivery
active ingredient
controlled release
Prior art date
Application number
EA201590805A
Other languages
Russian (ru)
Inventor
Вариндер АХУДЖА
Раджан Верма
Умеш Винаякрао Барабде
Арне Хагстен
Кристин ВАННЕРБЕРГЕР
Рамбабу Бооругу
Амол Виласрао Сомванши
Original Assignee
Ферринг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферринг Б.В. filed Critical Ферринг Б.В.
Publication of EA201590805A1 publication Critical patent/EA201590805A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение относится к быстрорастворимым фармацевтическим композициям, содержащим активный ингредиент, предназначенный для немедленного высвобождения, и дополнительно содержащим лекарственную форму с контролируемым высвобождением, содержащую активный ингредиент, предназначенный для контролируемого высвобождения.This invention relates to instant pharmaceutical compositions containing an active ingredient intended for immediate release, and further comprising a controlled release dosage form containing the active ingredient intended for controlled release.

EA201590805A 2012-11-21 2013-11-21 COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY EA201590805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
EA201590805A1 true EA201590805A1 (en) 2015-11-30

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590805A EA201590805A1 (en) 2012-11-21 2013-11-21 COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY

Country Status (18)

Country Link
EP (1) EP2922525A1 (en)
JP (1) JP2016500088A (en)
KR (1) KR20150085826A (en)
CN (1) CN104797240A (en)
AR (1) AR093585A1 (en)
AU (1) AU2013349682A1 (en)
BR (1) BR112015011430A2 (en)
CA (1) CA2891365A1 (en)
EA (1) EA201590805A1 (en)
HK (1) HK1213779A1 (en)
IL (1) IL238648A0 (en)
IN (1) IN2015DN03984A (en)
MX (1) MX2015006399A (en)
PH (1) PH12015501096A1 (en)
SG (2) SG10201703388TA (en)
TW (1) TW201422254A (en)
WO (1) WO2014079922A1 (en)
ZA (1) ZA201503603B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814753B2 (en) 2013-07-23 2017-11-14 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
KR20150144209A (en) * 2014-06-16 2015-12-24 훼링 비.브이. Pharmaceutical composition comprising stabilized desmopressin or pharmaceutically acceptable salt thereof
ES2923438T3 (en) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Compositions comprising low doses of desmopressin in combination with an alpha-adrenergic receptor antagonist
AU2015377223A1 (en) 2015-01-12 2017-08-31 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
SG11201805810PA (en) * 2015-09-01 2018-08-30 Wellesley Pharmaceuticals Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
SG11201805527QA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (en) * 2015-11-23 2017-08-01 魏斯理製藥公司 Composition for reducing frequency of urination, method of making and use thereof
CA3008628A1 (en) * 2015-12-18 2017-06-22 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
CN109069439A (en) 2016-04-21 2018-12-21 瓦尔库里亚公司 For pre-processing the composition and method of cancer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7042275B2 (en) * 2017-01-11 2022-03-25 フェリング・ベー・フェー Fast-disintegrating pharmaceutical composition
WO2019039836A2 (en) * 2017-08-22 2019-02-28 아주대학교산학협력단 Complex formulation composition for treatment of neurodegenerative disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003184A1 (en) 1996-07-19 1998-01-29 Clarke-Garegg, Margaret, A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (en) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003233118B8 (en) * 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (en) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 Oral cavity quick dissolving preparation and production method thereof
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (en) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 Slow-release particle and a production method therefor
WO2011013082A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011120904A2 (en) 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (en) * 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
MX356601B (en) * 2010-03-30 2018-05-29 Productos Maver S A De C V Pharmaceutical combination with anti-migraine effect, in solid presentation of extended release.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
CN104797240A (en) 2015-07-22
SG11201503913TA (en) 2015-06-29
EP2922525A1 (en) 2015-09-30
HK1213779A1 (en) 2016-07-15
PH12015501096A1 (en) 2015-07-27
ZA201503603B (en) 2016-01-27
AR093585A1 (en) 2015-06-10
IL238648A0 (en) 2015-06-30
TW201422254A (en) 2014-06-16
CA2891365A1 (en) 2014-05-30
KR20150085826A (en) 2015-07-24
IN2015DN03984A (en) 2015-10-02
WO2014079922A1 (en) 2014-05-30
JP2016500088A (en) 2016-01-07
AU2013349682A1 (en) 2015-06-04
MX2015006399A (en) 2015-07-21
BR112015011430A2 (en) 2017-07-11
SG10201703388TA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
IL244206A0 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
MX2015008628A (en) Boronic acid derivatives and therapeutic uses thereof.
NI201500135A (en) PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
MY173521A (en) Trpv4 antagonists
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX344846B (en) COMBINATION OF ACTIVE LOADED GRANULES WITH ADDITIONAL ASSETS.
EA201591830A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING EVEROLIMUS
PH12014502366B1 (en) Injectable formulation
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
EA201591196A1 (en) COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF HORMONES AND OTHER MEDICINES
PH12013502325A1 (en) Drug delivery system
EA201590405A1 (en) PREPARATION OF DRIED LIPOS FOR APPLICATION IN THE SYSTEMS OF THE ISSUE IN A PRESSED TYPE
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
HK1208188A1 (en) Formulations for the delivery of active ingredients
EA201491517A1 (en) N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DIHYDROXI-1-METHYL-2-OXO-3-HINOLINKARBOXAMID, ITS PREPARATION AND APPLICATION
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
EA201690395A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING BISOPROLOL AND RAMIPRIL